Key regions: Japan, India, Italy, Brazil, South Korea
The demand for Anti-Hypertensive Drugs in Western Asia has been growing steadily in recent years.
Customer preferences: The primary customer base for Anti-Hypertensive Drugs in Western Asia is the aging population, which is increasing in number. The preference for branded drugs over generic ones is also a significant trend in the market. Patients in the region have a higher inclination towards combination therapies over monotherapy.
Trends in the market: Saudi Arabia and the United Arab Emirates are the two largest markets for Anti-Hypertensive Drugs in Western Asia. The market is dominated by a few major players, with Novartis being the leading company in the region. The trend towards self-medication and online purchase of drugs is also on the rise in the region. The market is expected to witness a shift towards more innovative and effective drug therapies in the coming years.
Local special circumstances: The healthcare infrastructure in Western Asia is rapidly developing, with an increased focus on preventive care and chronic disease management. The region has a high prevalence of hypertension, which is a significant driver of the Anti-Hypertensive Drugs market. The market is also influenced by the regulatory environment in the region, which is relatively stringent compared to other emerging markets.
Underlying macroeconomic factors: The economic growth in Western Asia has been robust in recent years, driven by high oil prices and government investments in infrastructure and healthcare. The increasing disposable income and changing lifestyle habits have resulted in a rise in chronic diseases such as hypertension. The growing awareness of the importance of early diagnosis and treatment of hypertension is also driving the demand for Anti-Hypertensive Drugs in the region. The market is expected to continue its growth trajectory in the coming years, driven by these underlying macroeconomic factors.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
